Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. Submission

With extensive use of inhaled insulin expected "right out of the box," the development partners are focused on getting Exubera through, not to, regulatory agencies as quickly as possible, Pfizer CFO Shedlarz says.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By 

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

India’s R&D Financing Effort: Catalytic To De-Risking Early Innovation?

 

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

Defining Unmet Medical Need: EU Debate Sparks Concern Over Innovation And Access

 

Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.